Home Cart 0 Sign in  

[ CAS No. 50637-83-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 50637-83-7
Chemical Structure| 50637-83-7
Structure of 50637-83-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 50637-83-7 ]

Related Doc. of [ 50637-83-7 ]

Alternatived Products of [ 50637-83-7 ]

Product Details of [ 50637-83-7 ]

CAS No. :50637-83-7 MDL No. :MFCD24186238
Formula : C12H8Br2O Boiling Point : -
Linear Structure Formula :- InChI Key :CVLAZUXWINTOCV-UHFFFAOYSA-N
M.W : 328.00 Pubchem ID :12698898
Synonyms :

Calculated chemistry of [ 50637-83-7 ]

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.08
Num. rotatable bonds : 2
Num. H-bond acceptors : 1.0
Num. H-bond donors : 0.0
Molar Refractivity : 69.71
TPSA : 17.07 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.22 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.49
Log Po/w (XLOGP3) : 4.34
Log Po/w (WLOGP) : 4.18
Log Po/w (MLOGP) : 3.82
Log Po/w (SILICOS-IT) : 4.51
Consensus Log Po/w : 3.87

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.97
Solubility : 0.00352 mg/ml ; 0.0000107 mol/l
Class : Moderately soluble
Log S (Ali) : -4.41
Solubility : 0.0127 mg/ml ; 0.0000386 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -6.11
Solubility : 0.000258 mg/ml ; 0.000000785 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.66

Safety of [ 50637-83-7 ]

Signal Word:Danger Class:8
Precautionary Statements:P264-P270-P271-P280-P303+P361+P353-P304+P340-P305+P351+P338-P310-P330-P331-P363-P403+P233-P501 UN#:3261
Hazard Statements:H302-H314 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 50637-83-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 50637-83-7 ]
  • Downstream synthetic route of [ 50637-83-7 ]

[ 50637-83-7 ] Synthesis Path-Upstream   1~10

  • 1
  • [ 1590-25-6 ]
  • [ 50637-83-7 ]
YieldReaction ConditionsOperation in experiment
76%
Stage #1: for 0.166667 h;
Stage #2: for 4 h;
Intermediate 4: 2-Bromo-l-(6-bromo-2-naphthalenyl)ethanone (Scheme 1); To the l-(6-bromo-2-naphthalenyl)ethanone (lg, 4.01 mmol) dissolved in acetic acid (5ml) was added pyridinium tribromide (1.28 g, 4.01 mmol) and stirred for lOmin. HBr (33percent in acetic acid, 1.321 ml, 8.03 mmol) was added slowly and the solution was stirred for 4h. Yellow precipitation was noticed. The reaction mixture was quenched by adding cold sat NaHC03 solution and the precipitate formed was filtered and washed with water and dried.Yield : 76.0percent'H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.50 (s, 1 H), 8.03 - 8.13 (m, 2 H), 7.79 - 7.91 (m, 2 H), 7.67(dd, J=8.8, 1.5 Hz, 1 H), 4.57 (s, 2 H).
73% at 20℃; Bromine (3.32 g, 1.07 ml, 20.8 mmol) was added to a heated solution of 1-(6-bromonaphthalen-2-yl)ethanone (5.18 g, 20.8 mmol) in acetic acid (100 mL).
Left to cool to rt overnight.
The precipitate was filtered, washed with Et2O and dried under vacuum to give 2-bromo-1-(6-bromonaphthalen-2-yl)ethanone (5.02 g, 73percent).
70% With copper bromide In chloroform; ethyl acetate at 10℃; Reflux S2 (249.1 mg, 1.0 mmol) andCopper bromide (223.4 mg, 1.5 mmol)Add 25mL dried egg-shaped bottle,Add 5mL ethyl acetate and 5mL chloroform solution at room temperature to make the raw material completely dissolved,Then refluxed overnight. TLC tracking until the conversion of raw materials is completed,Remove the solvent after stopping heating to room temperature.Ethyl acetate was added to the bottle to dissolve it, followed by saturated brine and waterThe combined organic phases were dried over anhydrous sodium sulfate.After concentration under reduced pressure, the crude product was purified by column chromatography (petroleum ether → petroleum ether:Ethyl acetate = 20: 1) to give S3 (230.1 mg, 70percent yield) as a white solid.
67% With bromine In dichloromethane at 15℃; Step A - Synthesis of compound Int-39b Compound Int-39a (6 g, 24.09 mmol) in CH2C12 (80 mL) was treated dropwise with Br2 (1.253 mL, 24.33 mmol). The mixture was allowed to stir for about 15 hours then concentrated in vacuo. The residue obtained was recrystalhzed from THF to provide compound Int-39b, which was dried in vacuo (5.3g; 67percent).
37.82% at 20℃; for 1 h; Compound AA_072-2 (3.5 g, 14.06 mmol) was dissolved in acetic acid (30 mL), liquid bromine (2.2 g, 14.06 mmol) was dripped slowly. After dripping, the reaction mixture was stirred at room temperature for 1 h. After the reaction was complete as detected by TLC, H2O (80 mL) was added. The reaction mixture was filtrated and the solid was collected to deliver the target compound AA_072-3 (white solid, 1.74 g, yield 37.82percent). The product was directly used for the next step without purification. 1H NMR (CDCl3, 400 MHz): δ 8.12-8.05 (m, 2H), 7.88-7.85 (m, 3H), 7.83-7.68 (m, 1H), 4.56 (s, 2H).
7 g With bromine In 1,4-dioxane; dichloromethane at 10℃; for 2 h; To a solution of bromide B-la (5.0 g, 20.07 mmol) in DCM (150 mL) was added B (0.827 mL, 16.06 mmol) in dioxane (50 mL) over 10 minutes at 10 °C and the reaction mixture was stirred at 10 °C for 2 h. The reaction mixture was quenched with 10percent aHC03and extracted with DCM. The organic layer was dried over Na2S04and concentrated to obtain crude dibromide B-lb (7.0 g) as a yellow solid. NMR (CDC13), δ = 7.26 ppm, 400 MHz): δ 8.48 (s, 1 H), 8.07- 8.04 (m, 2 H), 7.85 (d, J = 8.8, 1 H), 7.84 (d, J = 8.8, 1 H), 7.66 (dd, J = 8.8, 2.0, 1 H), 4.55 (s, 2 H).

Reference: [1] Patent: WO2011/91446, 2011, A1, . Location in patent: Page/Page column 7; 11
[2] Patent: US2012/230951, 2012, A1, . Location in patent: Page/Page column 85
[3] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2011, vol. 50, # 4, p. 593 - 604
[4] Patent: CN107286150, 2017, A, . Location in patent: Paragraph 0132; 0133; 0134; 0135
[5] Patent: WO2013/39878, 2013, A1, . Location in patent: Page/Page column 109; 110
[6] Patent: US2017/253614, 2017, A1, . Location in patent: Paragraph 0574; 0576
[7] Justus Liebigs Annalen der Chemie, 1973, p. 1112 - 1140
[8] Journal of Medicinal Chemistry, 1981, vol. 24, # 1, p. 67 - 74
[9] Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical, 1984, vol. 23, # 12, p. 1008 - 1010
[10] Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical, 1984, vol. 23, # 12, p. 1008 - 1010
[11] Patent: US2011/64695, 2011, A1, . Location in patent: Page/Page column 94
[12] Patent: US2011/64697, 2011, A1, . Location in patent: Page/Page column 85
[13] Patent: US2011/64698, 2011, A1, . Location in patent: Page/Page column 87
[14] Patent: WO2011/54834, 2011, A1,
[15] Patent: WO2012/13643, 2012, A1, . Location in patent: Page/Page column 26
[16] Patent: US2012/219594, 2012, A1,
[17] Patent: US2015/23913, 2015, A1, . Location in patent: Paragraph 0995-0996
[18] Patent: WO2015/5901, 2015, A1, . Location in patent: Page/Page column 370
[19] Patent: US9127021, 2015, B2, . Location in patent: Page/Page column 153
[20] Patent: WO2010/99527, 2010, A1, . Location in patent: Page/Page column 118
  • 2
  • [ 1256387-44-6 ]
  • [ 50637-83-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 5, p. 2033 - 2046
[2] Patent: WO2010/132601, 2010, A1, . Location in patent: Page/Page column 594-595
  • 3
  • [ 1303533-76-7 ]
  • [ 50637-83-7 ]
YieldReaction ConditionsOperation in experiment
50% With triethylamine; phosphonic acid diethyl ester In tetrahydrofuran 1- (6-bromonaphthalen-2-yl)ethanone (55.6 g, 223 mmol, 1.0 equiv.) was dissolved in dichloromethane (1.3 L). Dibromine (78.3 g, 490 mmol, 2.2 equiv.) was added drop wise during 30 minutes. The reaction mixture was stirred 1 hour and concentrated to afford 2,2-dibromo-l-(6-bromonaphthalen-2-yl)ethanone as a solid which was used as such in next step.2,2-dibromo-l-(6-bromonaphthalen-2-yl)ethanone (90.0 g, 221 mmol, 1.00) was dissolved in tetrahydrofurane (800 mL), triethylamine (27.67 mL, 199 mmol,0.9 equiv.) was added followed by diethyl phosphite (45.8 g, 332 mmol, 1.50 equiv.). The reaction mixture was stirred overnight. The reaction mixture was filtrated and the solvent was removed in vacuum. The obtained residue was dissolved in ethyl acetate (1.2 L) and washed with water. The organic layer was separated, dried over sodium sulphate, filtrated and concentrated to yield crude 2-bromo-l-(6-bromonaphthalen-2- yl)ethanone (70.3 g). Recrystallization from acetonitrile gave 30 g (first batch) and 6.5 g (second batch) of 2-bromo-l-(6-bromonaphthalen-2-yl)ethanone (50 percent)
Reference: [1] Patent: WO2011/54834, 2011, A1, . Location in patent: Page/Page column 39-40
  • 4
  • [ 1256387-44-6 ]
  • [ 50637-83-7 ]
Reference: [1] Patent: US2011/306541, 2011, A1,
  • 5
  • [ 762-04-9 ]
  • [ 1303533-76-7 ]
  • [ 50637-83-7 ]
Reference: [1] Patent: US2012/219594, 2012, A1,
  • 6
  • [ 580-13-2 ]
  • [ 50637-83-7 ]
Reference: [1] Patent: WO2011/54834, 2011, A1,
[2] Patent: WO2012/13643, 2012, A1,
[3] Patent: US2012/219594, 2012, A1,
[4] Patent: US2015/23913, 2015, A1,
[5] Patent: WO2015/5901, 2015, A1,
  • 7
  • [ 5773-80-8 ]
  • [ 50637-83-7 ]
Reference: [1] Patent: WO2011/54834, 2011, A1,
[2] Patent: US2011/306541, 2011, A1,
[3] Patent: US2011/306541, 2011, A1,
[4] Patent: US2011/306541, 2011, A1,
[5] Patent: US2012/219594, 2012, A1,
[6] Patent: WO2011/91446, 2011, A1,
[7] Journal of Medicinal Chemistry, 2014, vol. 57, # 5, p. 2033 - 2046
[8] Patent: CN107286150, 2017, A,
[9] Patent: US2017/253614, 2017, A1,
[10] Patent: WO2010/132601, 2010, A1,
  • 8
  • [ 861880-64-0 ]
  • [ 50637-83-7 ]
Reference: [1] Patent: US2011/64695, 2011, A1,
[2] Patent: US2011/64697, 2011, A1,
[3] Patent: US2011/64698, 2011, A1,
[4] Patent: WO2011/54834, 2011, A1,
[5] Patent: US2012/219594, 2012, A1,
[6] Patent: WO2011/91446, 2011, A1,
[7] Patent: US9127021, 2015, B2,
[8] Patent: CN107286150, 2017, A,
[9] Patent: US2017/253614, 2017, A1,
[10] Patent: WO2010/99527, 2010, A1,
  • 9
  • [ 87700-60-5 ]
  • [ 50637-83-7 ]
Reference: [1] Patent: WO2011/54834, 2011, A1,
[2] Patent: US2011/306541, 2011, A1,
[3] Patent: US2012/219594, 2012, A1,
[4] Patent: WO2011/91446, 2011, A1,
[5] Journal of Medicinal Chemistry, 2014, vol. 57, # 5, p. 2033 - 2046
[6] Patent: CN107286150, 2017, A,
[7] Patent: WO2010/132601, 2010, A1,
  • 10
  • [ 186581-53-3 ]
  • [ 87700-60-5 ]
  • [ 50637-83-7 ]
  • [ 1256387-44-6 ]
Reference: [1] Patent: US2011/306541, 2011, A1,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 50637-83-7 ]

Ravidasvir Related Intermediates

Chemical Structure| 73183-34-3

[ 73183-34-3 ]

4,4,4',4',5,5,5',5'-Octamethyl-2,2'-bi(1,3,2-dioxaborolane)

Chemical Structure| 15761-39-4

[ 15761-39-4 ]

(S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid

Chemical Structure| 5773-80-8

[ 5773-80-8 ]

6-Bromo-2-naphthoic acid

Chemical Structure| 1575-37-7

[ 1575-37-7 ]

4-Bromobenzene-1,2-diamine

Chemical Structure| 74761-42-5

[ 74761-42-5 ]

MOC-Val-OH

Related Functional Groups of
[ 50637-83-7 ]

Aryls

Chemical Structure| 1016-77-9

[ 1016-77-9 ]

(3-Bromophenyl)(phenyl)methanone

Similarity: 0.85

Chemical Structure| 2142-63-4

[ 2142-63-4 ]

3'-Bromoacetophenone

Similarity: 0.85

Chemical Structure| 1379325-64-0

[ 1379325-64-0 ]

1-(3-Bromo-5-methylphenyl)ethanone

Similarity: 0.85

Chemical Structure| 216312-73-1

[ 216312-73-1 ]

3,6-Dibromo-9H-fluoren-9-one

Similarity: 0.83

Chemical Structure| 3988-03-2

[ 3988-03-2 ]

4,4'-Dibromobenzophenone

Similarity: 0.83

Bromides

Chemical Structure| 1016-77-9

[ 1016-77-9 ]

(3-Bromophenyl)(phenyl)methanone

Similarity: 0.85

Chemical Structure| 2142-63-4

[ 2142-63-4 ]

3'-Bromoacetophenone

Similarity: 0.85

Chemical Structure| 1379325-64-0

[ 1379325-64-0 ]

1-(3-Bromo-5-methylphenyl)ethanone

Similarity: 0.85

Chemical Structure| 216312-73-1

[ 216312-73-1 ]

3,6-Dibromo-9H-fluoren-9-one

Similarity: 0.83

Chemical Structure| 3988-03-2

[ 3988-03-2 ]

4,4'-Dibromobenzophenone

Similarity: 0.83

Ketones

Chemical Structure| 1016-77-9

[ 1016-77-9 ]

(3-Bromophenyl)(phenyl)methanone

Similarity: 0.85

Chemical Structure| 2142-63-4

[ 2142-63-4 ]

3'-Bromoacetophenone

Similarity: 0.85

Chemical Structure| 1379325-64-0

[ 1379325-64-0 ]

1-(3-Bromo-5-methylphenyl)ethanone

Similarity: 0.85

Chemical Structure| 216312-73-1

[ 216312-73-1 ]

3,6-Dibromo-9H-fluoren-9-one

Similarity: 0.83

Chemical Structure| 3988-03-2

[ 3988-03-2 ]

4,4'-Dibromobenzophenone

Similarity: 0.83